Everything below concerns Lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
===== MeSH D08.811.682.047 – alcohol oxidoreductases ===== MeSH D08.811.682.047.050 – acetoin dehydrogenase MeSH D08.811.682.047.070 – alcohol dehydrogenase MeSH D08.811.682.047.150 – carbohydrate dehydrogenases MeSH D08.811.682.047.150.225 – fructuronate reductase MeSH D08.811.682.047.150.250 – galactose dehydrogenases MeSH D08.811.682.047.150.270 – glucose dehydrogenases MeSH D08.811.682.047.150.270.500 – glucose 1-dehydrogenase MeSH D08.811.682.047.150.300 – glucosephosphate dehydrogenase MeSH D08.811.682.047.150.600 – phosphogluconate dehydrogenase MeSH D08.811.682.047.150.650 – phosphoglycerate dehydrogenase MeSH D08.811.682.047.150.700 – sugar alcohol dehydrogenases MeSH D08.811.682.047.150.700.075 – aldehyde reductase MeSH D08.811.682.047.150.700.237 – d-xylulose reductase MeSH D08.811.682.047.150.700.400 – glycerolphosphate dehydrogenase MeSH D08.811.682.047.150.700.400.500 – glycerol-3-phosphate dehydrogenase (nad+) MeSH D08.811.682.047.150.700.437 – l-gulonolactone oxidase MeSH D08.811.682.047.150.700.475 – l-iditol 2-dehydrogenase MeSH D08.811.682.047.150.700.649 – mannitol dehydrogenase MeSH D08.811.682.047.150.900 – uridine diphosphate glucose dehydrogenase MeSH D08.811.682.047.180 – choline dehydrogenase MeSH D08.811.682.047.210 – galactose oxidase MeSH D08.811.682.047.239 – glucose oxidase MeSH D08.811.682.047.370 – homoserine dehydrogenase MeSH D08.811.682.047.370.060 – aspartokinase homoserine dehydrogenase MeSH D08.811.682.047.385 – 3-hydroxyacyl coa dehydrogenases MeSH D08.811.682.047.385.415 – hydroxymethylglutaryl coa reductases MeSH D08.811.682.047.385.415.250 – hydroxymethylglutaryl-coa reductases, nad-dependent MeSH D08.811.682.047.385.415.750 – hydroxymethylglutaryl-coa-reductases, nadp-dependent MeSH D08.811.682.047.393 – hydroxybutyrate dehydrogenase MeSH D08.811.682.047.428 – Hydroxyprostaglandin dehydrogenase MeSH D08.811.682.047.432 – hydroxypyruvate reductase MeSH D08.811.682.047.436 – hydroxysteroid dehydrogenases MeSH D08.811.682.047.436.174 – 11-beta-hydroxysteroid dehydrogenases MeSH D08.811.682.047.436.174.300 – 11-beta-hydroxysteroid dehydrogenase type 1 MeSH D08.811.682.047.436.174.600 – 11-beta-hydroxysteroid dehydrogenase type 2 MeSH D08.811.682.047.436.350 – 3-hydroxysteroid dehydrogenases MeSH D08.811.682.047.436.350.100 – 3alpha-hydroxysteroid dehydrogenase (B-specific) MeSH D08.811.682.047.436.350.150 – cholesterol oxidase MeSH D08.811.682.047.436.350.700 – progesterone reductase MeSH D08.811.682.047.436.375 – 17-hydroxysteroid dehydrogenases MeSH D08.811.682.047.436.375.280 – estradiol dehydrogenases MeSH D08.811.682.047.436.400 – 20-hydroxysteroid dehydrogenases MeSH D08.811.682.047.436.400.074 – 20alpha-hydroxysteroid dehydrogenase MeSH D08.811.682.047.436.400.150 – cortisone reductase MeSH D08.811.682.047.485 – imp dehydrogenase MeSH D08.811.682.047.497 – isocitrate dehydrogenase MeSH D08.811.682.047.500 – 3-isopropylmalate dehydrogenase MeSH D08.811.682.047.524 – ketol-acid reductoisomerase MeSH D08.811.682.047.551 – lactate dehydrogenases MeSH D08.811.682.047.551.249 – epsilon-crystallins MeSH D08.811.682.047.551.400 – l-lactate dehydrogenase MeSH D08.811.682.047.551.500 – l-lactate dehydrogenase (cytochrome) MeSH D08.811.682.047.605 – malate dehydrogenase MeSH D08.811.682.047.748 – malate dehydrogenase (nadp+) MeSH D08.811.682.047.892 – xanthine dehydrogenase MeSH D08.811.682.047.928 – xanthine oxidase
When the protein is labelled with carbon-13 and nitrogen-15 it is possible to record triple resonance experiments that transfer magnetisation over the peptide bond, and thus connect different spin systems through bonds. This is usually done using some of the following experiments, HNCO, HN(CA)CO}, HNCA, HN(CO)CA, HNCACB and CBCA(CO)NH. All six experiments consist of a 1H-15N plane (similar to a HSQC spectrum) expanded with a carbon dimension. In the HN(CA)CO, each HN plane contains the peaks from the carbonyl carbon from its residue as well the preceding one in the sequence. The HNCO contains the carbonyl carbon chemical shift from only the preceding residue, but is much more sensitive than HN(CA)CO. These experiments allow each 1H-15N peak to be linked to the preceding carbonyl carbon, and sequential assignment can then be undertaken by matching the shifts of each spin system's own and previous carbons. The HNCA and HN(CO)CA works similarly, just with the alpha carbons (Cα) rather than the carbonyls, and the HNCACB and the CBCA(CO)NH contains both the alpha carbon and the beta carbon (Cβ). Usually several of these experiments are required to resolve overlap in the carbon dimension. This procedure is usually less ambiguous than the NOESY-based method since it is based on through bond transfer. In the NOESY-based methods, additional peaks corresponding to atoms that are close in space but that do not belong to sequential residues will appear, confusing the assignment process.
Temperature dependence: LED performance largely depends on the ambient temperature of the operating environment – or thermal management properties. Overdriving an LED in high ambient temperatures may result in overheating the LED package, eventually leading to device failure. An adequate heat sink is needed to maintain long life. This is especially important in automotive, medical, and military uses where devices must operate over a wide range of temperatures, and require low failure rates.
=== Metalloaminopeptidases === Metalloaminopeptidases require metal ions, such as zinc or manganese, in order to function. These enzymes can be identified by a conserved HEXXH motif in their active site. This motif is crucial for the enzyme's function, as the histidine amino acids within the motif coordinate (bind) the metal ion, which then uses hydrolysis to break the peptide bond between the first amino acid and the rest of the protein. Metalloaminopeptidases are the largest and most homogenous class of aminopeptidases; the MEROPS database identifies over 35 families to be part of the MA clan. This classification, which is based on structural similarities and evolutionary relationships, indicates a common ancestral origin for these enzymes. Examples of metalloaminopeptidases include aminopeptidase N (APN), leucine aminopeptidase (LAP), and aminopeptidase A (APA).
Sources: en.wikipedia.org
Penicillin-binding proteins (PBP) are a group of proteins that are characterized by their affinity for and binding of penicillin. They are a normal constituent of many bacteria; the name just reflects the way by which the protein was discovered. All β-lactam antibiotics (except for tabtoxinine-β-lactam, which inhibits glutamine synthetase) bind to PBPs, which are essential for bacterial cell wall synthesis. PBPs are members of a subgroup of transpeptidase enzymes called DD-transpeptidases.
=== Ion exchange mechanism === Another extraction mechanism is known as the ion exchange mechanism. Here, when an ion is transferred from the aqueous phase to the organic phase, another ion is transferred in the other direction to maintain the charge balance. This additional ion is often a hydrogen ion; for ion exchange mechanisms, the distribution ratio is often a function of pH. An example of an ion exchange extraction would be the extraction of americium by a combination of terpyridine and a carboxylic acid in tert-butyl benzene. In this case
This is a list of published International Organization for Standardization (ISO) standards and other deliverables. For a complete and up-to-date list of all the ISO standards, see the ISO catalogue. The standards are protected by copyright and most of them must be purchased. However, about 300 of the standards produced by ISO and IEC's Joint Technical Committee 1 (JTC 1) have been made freely and publicly available.
=== Selected articles === Ajayaghosh, Ayyappanpillai, Subi J. George (2001). “First phenylenevinylene based organogels: self-assembled nanostructures via cooperative hydrogen bonding and π-stacking”. J. Am. Chem. Soc. 2001, 123, 21, 5148-5149. https://doi.org/10.1021/ja005933+. Ajayaghosh, Ayyappanpillai, Priya Carol, and Sivaramapanicker Sreejith (2005) “A Ratiometric Fluorescence Probe for Selective Visual Sensing of Zn2+”. J. Am. Chem. Soc. 2005, 127, 43, 14962-14963. https://doi.org/10.1021/ja054149s. Ajayaghosh, Ayyappanpillai, Vakayil K. Praveen, Chakkooth Vijayakumar, Subi J. George (2007). “Molecular Wire Encapsulated into π Organogels: Efficient Supramolecular Light-Harvesting Antennae with Color-Tunable Emission”. Angew. Chem. Int. Ed. 2007, 46, 6260-6265. https://doi.org/10.1002/anie.200701925. Ajayaghosh, Ayyappanpillai, Vakayil K. Praveen (2008). “π-Organogels of Self-Assembled p-Phenylenevinylenes: Soft Materials with Distinct Size, Shape, and Functions”. Acc. Chem. Res. 2007, 40, 8, 644-656. https://doi.org/10.1021/ar7000364 Vijayakumar, Chakkooth; Praveen, Vakayil K.; Kartha, Kalathil K.; Ajayaghosh, Ayyappanpillai (2011). "Excitation energy migration in oligo(p-phenylenevinylene) based organogels: structure-property relationship and FRET efficiency". Physical Chemistry Chemical Physics. 13 (11): 4942–4949. Bibcode:2011PCCP...13.4942V. doi:10.1039/C0CP02110E. PMID 21321716. S2CID 19328938. Kartha, Kalathil K.; Babu, Sukumaran S.; Srinivasan, Sampath; Ajayaghosh, Ayyappanpillai (2012).
== Structure == The parenchyma is the functional parts of an organ, or of a structure such as a tumour in the body. This is in contrast to the stroma, which refers to the structural tissue of organs or of structures, namely, the connective tissues.
Sources: en.wikipedia.org
==== Canaloplasty ==== Canaloplasty is a nonpenetrating procedure using microcatheter technology. To perform a canaloplasty, an incision is made into the eye to gain access to the Schlemm's canal, similarly to a viscocanalostomy. A microcatheter will circumnavigate the canal around the iris, enlarging the main drainage channel and its smaller collector channels through the injection of a sterile, gel-like material called viscoelastic. The catheter is then removed, and a suture is placed within the canal and tightened. By opening the canal, the pressure inside the eye may be relieved, although the reason is unclear, since the canal (of Schlemm) does not have any significant fluid resistance in glaucoma or healthy eyes. Long-term results are not available.
=== Acute bone fracture care === Bone fractures are treated in individuals with osteogenesis imperfecta in much the same way as they are treated in the general population; OI bone heals at the same rate as non-OI bone. A greater emphasis is placed on using lightweight materials to immobilize the fracture, as in moderate or severe types of OI, using heavy casts, such as hip spica casts, can cause fractures at the bones at the boundaries of the cast, as well as generalized osteopenia. The lightweight cast or splint is then replaced with a removable orthosis after a few weeks and once evidence of union is seen on X-ray. To prevent a nonunion or malunion, all fractures should be immobilized, even if the fracture seems trivial (microfracture), as people with OI are at greater risk of nonunion. Bone infections secondary to fractures are treated as and when they occur with the appropriate antibiotics and antiseptics, as in the general population.
In molecular biology, the type IV collagen C4 domain (or collagen IV NC1 domain) is a duplicated domain present at the C-terminus of type IV collagens. Each type IV collagen contains a long triple-helical collagenous domain flanked by a short 7S domain of 25 amino acids and a globular non-collagenous C4 domain of ~230 amino acids at the N and C terminus, respectively. In protomer assembly, the C4 domains of three chains interact, forming a C4 trimer, to select and register chains for triple helix formation. In network assembly, the C4 trimers of two protomers interact, forming a C4 hexamer structure, to select and connect protomers. The collagen IV C4 domain contains 12 cysteines, and all of them are involved in disulphide bonds. It folds into a tertiary structure with predominantly beta-strands. The collagen IV C4 domain is composed of two similarly folded subdomains stabilised by 3 intrachain disulphide bonds involving the following pairs: C1-C6, C2-C5, and C3-C4. Each subdomain represents a compact disulphide-stabilised triangular structure, from which a finger-like hairpin loop projects into an incompletely formed six-stranded beta-sheet of an adjacent subdomain of the same or of an adjacent chain clamping the subdomains tightly together.
==== Peripheral nervous system ==== ColVI is expressed by Schwann cells in the peripheral nervous system. It is present in the connective tissue of the endoneurium, perineurium, and epineurium. ColVI has been shown to be expressed by immature Schwann cells when they begin to differentiate into myelinating cells, suggesting that ColVI plays an integral role in regulating Schwann cell differentiation. ColVI also plays a key role in the peripheral nervous system myelination and maintains proper functioning of the sciatic nerve.
FACIT collagen (Fibril Associated Collagens with Interrupted Triple helices) is a type of collagen and also a proteoglycan that have two or more triple-helical domains that connect to collagen fibrils and share protein domains with non-collagen matrix molecules. FACIT collagens derive their name from their association and interaction with fibrillar collagens. Unlike fibrillar collagens, which form long fibers.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.